{"id":51783,"date":"2025-12-22T21:31:16","date_gmt":"2025-12-22T13:31:16","guid":{"rendered":"https:\/\/flcube.com\/?p=51783"},"modified":"2025-12-22T21:31:16","modified_gmt":"2025-12-22T13:31:16","slug":"grand-pharmaceuticals-tlx591-cdx-rdc-wins-china-phase-iii-for-prostate-cancer-diagnosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51783","title":{"rendered":"Grand Pharmaceutical\u2019s TLX591\u2011CDx RDC Wins China Phase III for Prostate Cancer Diagnosis"},"content":{"rendered":"\n

Grand Pharmaceutical Group Limited<\/strong> (HKG: 0512<\/a>) announced that its China\u2011based Phase\u202fIII clinical trial<\/strong> for TLX591\u2011CDx (Illuccix, gallium Ga\u202f68 PSMA\u201111)<\/strong> achieved positive topline results<\/strong> and met its primary endpoint. The investigational Radiopharmaceutical Drug Conjugate (RDC)<\/strong> for prostate cancer diagnosis is a global\u2011first<\/strong> diagnostic agent based on radionuclide\u2011small molecule conjugation technology.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Details<\/th><\/tr><\/thead>
Trial Completion<\/strong><\/td>Positive topline results; primary endpoint met<\/td><\/tr>
Product<\/strong><\/td>TLX591\u2011CDx (Illuccix)<\/td><\/tr>
Mechanism<\/strong><\/td>Targets Prostate\u2011Specific Membrane Antigen (PSMA)<\/td><\/tr>
Innovation<\/strong><\/td>Global\u2011first diagnostic RDC for prostate cancer<\/td><\/tr>
Key Attributes<\/strong><\/td>Internalization, stable activity, short half\u2011life, tumor permeability, rapid non\u2011target clearance<\/td><\/tr>
Indication<\/strong><\/td>Diagnosis of newly diagnosed and recurrent prostate cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Global Commercial Footprint<\/h2>\n\n\n\n
Year<\/th>Markets\/Approvals<\/th><\/tr><\/thead>
2021<\/strong><\/td>Australia (Nov), United States (Dec)<\/td><\/tr>
2022<\/strong><\/td>Canada (Oct)<\/td><\/tr>
2023\u20112024<\/strong><\/td>Expanded indications in US, Australia, Canada for PSMA\u2011targeted therapy screening<\/td><\/tr>
2025<\/strong><\/td>21 European\/international markets (UK, Germany, France, Italy, Spain, Brazil, Norway)<\/td><\/tr>
2026 (Projected)<\/strong><\/td>China NDA submission based on Phase\u202fIII data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Opportunity & Competitive Landscape<\/h2>\n\n\n\n
Metric<\/th>Value<\/th>Context<\/th><\/tr><\/thead>
China Prostate Cancer Incidence<\/strong><\/td>~120,000 new cases (2025)<\/td>Growing diagnosis rate; high recurrence risk<\/td><\/tr>
China RDC Market<\/strong><\/td>\u00a52\u20113\u202fbillion<\/strong> (\u2248\u202fUS$280\u2011420\u202fM)<\/td>Radiopharmaceuticals gaining traction in oncology<\/td><\/tr>
PSMA\u2011Targeted Market<\/strong><\/td>$1.2\u202fbillion<\/strong> globally (2025)<\/td>Dominated by PET\/CT imaging agents<\/td><\/tr>
TLX591\u2011CDx Peak Sales<\/strong><\/td>\u00a5500\u2011800\u202fmillion<\/strong> (\u2248\u202fUS$70\u2011112\u202fM) by 2030<\/td>40\u201150% share of China PSMA\u2011RDC segment<\/td><\/tr>
Competitive Advantage<\/strong><\/td>First global RDC with proven efficacy across 25+ markets<\/td>Regulatory pathway validated; cost vs. PET\/CT favorable<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n